Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX-TARAV study of bevacizumab, erlotinib, oxaliplatin, and capecitabine in metastatic colorectal cancer
2005-005548-21Phase 2Terminated
- Sponsor
- Consorzio Oncotech
- Start
- Sep 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, erlotinib, oxaliplatin and capecitabine in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Consorzio Oncotech. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicity and 2 more. Started Sep 2009; status: terminated.
02
Drugs
bevacizumaberlotiniboxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2005-005548-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005548-21.